19246-24-3

Usage

Uses

Used in Pharmaceutical Industry:
Telomycin is used as an antibiotic for its potent and highly selective activity against Gram-positive bacteria. This makes it a valuable compound in the fight against bacterial infections caused by these types of bacteria.
Used in Research and Development:
Due to its unique structure and properties, telomycin can be used as a research tool to study the mechanisms of action against Gram-positive bacteria. This could potentially lead to the development of new antibiotics or therapies targeting these bacteria.
Used in Veterinary Medicine:
Telomycin's potent activity against Gram-positive bacteria may also find applications in veterinary medicine, where it could be used to treat bacterial infections in animals.

InChI:InChI=1/C60H79N13O19/c1-26(2)50(80)47-58(88)73-18-16-42(77)49(73)60(91)92-30(6)35(23-64-53(83)40(25-74)67-43(78)20-36(61)59(89)90)52(82)70-46(29(5)75)56(86)66-28(4)51(81)65-24-44(79)72-17-15-41(76)48(72)57(87)68-39(19-31-21-62-37-13-9-7-11-32(31)37)54(84)69-45(55(85)71-47)27(3)34-22-63-38-14-10-8-12-33(34)38/h7-14,19,21-22,26-30,35-36,40-42,45-50,62-63,74-77,80H,15-18,20,23-25,61H2,1-6H3,(H,64,83)(H,65,81)(H,66,86)(H,67,78)(H,68,87)(H,69,84)(H,70,82)(H,71,85)(H,89,90)

Relevant academic research and scientific papers

Biosynthetic Studies of Telomycin Reveal New Lipopeptides with Enhanced Activity

Telomycin (TEM) is a cyclic depsipeptide antibiotic active against Gram-positive bacteria. In this study, five new natural telomycin analogues produced by Streptomyces canus ATCC 12646 were identified. To understand the biosynthetic machinery of telomycin and to generate more analogues by pathway engineering, the TEM biosynthesis gene cluster has been characterized from S. canus ATCC 12646: it spans approximately 80.5 kb and consists of 34 genes encoding fatty acid ligase, nonribosomal peptide synthetases (NRPSs), regulators, transporters, and tailoring enzymes. The gene cluster was heterologously expressed in Streptomyces albus J1074 setting the stage for convenient biosynthetic engineering, mutasynthesis, and production optimization. Moreover, in-frame deletions of one hydroxylase and two P450 monooxygenase genes resulted in the production of novel telomycin derivatives, revealing these genes to be responsible for the specific modification by hydroxylation of three amino acids found in the TEM backbone. Surprisingly, natural lipopeptide telomycin precursors were identified when characterizing an unusual precursor deacylation mechanism during telomycin maturation. By in vivo gene inactivation and in vitro biochemical characterization of the recombinant enzyme Tem25, the maturation process was shown to involve the cleavage of previously unknown telomycin precursor-lipopeptides, to yield 6-methylheptanoic acid and telomycins. These lipopeptides were isolated from an inactivation mutant of tem25 encoding a (de)acylase, structurally elucidated, and then shown to be deacylated by recombinant Tem25. The TEM precursor and several semisynthetic lipopeptide TEM derivatives showed rapid bactericidal killing and were active against several multidrug-resistant (MDR) Gram-positive pathogens, opening the path to future chemical optimization of telomycin for pharmaceutical application. (Chemical Equation Presented).